Context-Of-Use Scoping Before Any Platform
- Exploratory, fit-for-purpose, GCLP or CLIA, decided from how the data will be used
- The tier is named in the quote with what it includes, so upgrades are planned, not painful
Services
Platforms
Solutions
About Us
Resources
De-Risk Your Biomarker Assay, Fit-For-Purpose to GLP/CLIA.
Brief PhDs on your biomarker, matrix and study.- Context-Of-Use Tiering From Exploratory Through Fit-For-Purpose To GCLP And CLIA
- Soluble, Cellular And Molecular Biomarkers On Seven Platforms Under One Study Roof
- An 851 Item Assay Menu With Species Variants, Searchable Before You Ever Ask Us
- 100+ Sponsors Every Year, Two Thirds Returning, One In Three Past A Third Year
Regulated And Inspected By:
The Tier Question Decides Everything, So It Comes First
An exploratory panel, a PD endpoint and an enrollment marker are three different validation jobs. We scope the context of use before the platform, so you pay for the tier your decision needs.
LC-MS Biomarkers Where Antibodies Fall Short
- Amino acids, small molecule markers and hybrid LC-MS when no antibody pair exists
- The Q Exactive HF Orbitrap for discovery proteomics and targeted confirmation after it
Soluble Biomarkers On MSD, Luminex And ELISA
- Single analyte to 50-plex panels, with S-PLEX sensitivity when femtogram levels decide
- Prevalidated cytokine and inflammation panels beside fully custom builds for novel markers
PD Endpoints And Target Engagement, Study Grade
- Dose and exposure response readouts qualified to carry pharmacodynamic conclusions
- Cut points and parallelism handled statistically, so the endpoint holds up in QA review
Cellular And Molecular Readouts In The Same Study
- Receptor occupancy and immunophenotyping by flow, T-cell response by ELISpot on site
- Gene expression and copy number by validated qPCR and ddPCR right beside the protein data
Trial Enrollment And Stratification Under CLIA
- Patient-level biomarker cut-offs reported inside screening windows for site decisions
- The same lab then runs the longitudinal endpoint, with one method bridging both purposes
The Biomarker Tier Ladder, In Order Of Weight
The tiers run from exploratory through fit-for-purpose and GCLP to GLP, then CLIA for any result that routes a patient.
-
Exploratory
Hypothesis generation on research-grade rigor, priced and documented as exactly that
Non-GLP Testing -
Fit-For-Purpose
Qualified for its context of use, the workhorse tier for most PD and stratification calls
-
GCLP For Clinical Trials
Clinical-sample rigor with cut points and trending your submission can stand on
Clinical CRO -
GLP Where Safety Reads It
Full validation under Part 58 when the marker feeds a safety or regulatory decision
Method Validation -
CLIA For Enrollment Calls
When a result routes a patient, the assay runs under CLIA discipline
-
The Tier Can Climb
Start exploratory, graduate the same assay upward with its history intact
Bioanalytical Assay
Ready To Start? Scope Your Biomarker Assay.
Tailored biomarker quote in 2 days.
A Biomarker Is Only Worth What Its Validation Tier Can Defend
Programs fail when context of use is settled after the data. We put it in writing before the first sample.
Talk Science First? Ask Our Biomarker Experts.
Discuss context of use and validation tier.- Fit-for-purpose qualification runs in about six to eight weeks with the tier named in the quote, so an exploratory budget is never spent buying GCLP paperwork the decision does not need.
- Seven platforms under one roof mean the analyte picks the technology rather than the lab defending its only instrument, and one draw feeds protein, cellular and molecular readouts.
- Where the marker gates enrollment or stratification, CLIA and CAP cover patient-level reporting, and the same laboratory carries the longitudinal endpoint so nothing re-bridges.
1,000+Biomarker And Cytokine Assays Developed And Delivered
6-8Weeks To A Fit-For-Purpose Biomarker Qualification
What Does Biomarker Work Cost?
Tier drives price, so the quote names the tier and what it includes. Menu assays skip development entirely, fit-for-purpose qualification runs in about six to eight weeks, and there is no minimum batch size, so exploratory panels start small and scale. A senior scientist replies within two business days.
Your Cost Cannot Move Mid-Study
The quote you approve is the price you pay. Cost cannot move mid-study without an SOW addendum you have already approved, which matters most on longitudinal biomarker work that runs the length of a trial.
Straight From Sponsors: Assays Built To Their Programs
Biomarker programs stretch across years, and so do these relationships. One in three sponsors stays with us past a third year.
-
VP, Biomarker Development
NorthEast BioLab is a responsive, collaborative, and reliable partner
-
VP, Clinical Stage Biotech
There is also a willingness to develop new services to meet our needs even if not currently offered.
-
VP, Clinical Stage Biotech
The services are customized to our specific needs as opposed to standard packages.
-
Sr. Dir., Bioanalytical Development & QC
NorthEast BioLab offers a science-based, hands-on approach to the latest bioanalytical platforms
-
Executive Director, Pharmacokinetics
We trust NorthEast BioLab to design and execute streamlined, impactful bioanalytical projects
-
Scientist, Clinical Stage Biotech
I appreciate your team’s willingness to answer questions and provide guidance.
Need a Biomarker Assay? Validated Kit or Custom Build.
Share the marker and context of use. We'll design it.Why Translational Teams Bring Us The Markers Their Programs Turn On
Our biomarker work spans exploratory panels to primary endpoints over 20+ years, on ELISA, MSD, flow and LC-MS.
What You Receive
- A qualification report matched to the context of use, with cut points set statistically
- Decision grade data tables, trend ready, timed to your interim and database lock dates
- One accession feeding protein, cellular and molecular readouts under a single custody
- A method that carries from exploratory into GCLP or CLIA without starting over again
What We Need From You
- The decision the marker drives, in a sentence, because that sentence sets the tier
- Analyte, matrix and species, so the menu check happens before anything is quoted
- Reference material or kit preference if you hold one, and we source it if you do not
- Your draw schedule and volumes, so panels multiplex instead of draining the sample
Biomarker Assay List
Biomarker research, discovery, and qualification are pivotal in modern drug development from demonstrating proof-of-concept (POC) to establishing drug safety and….
One Target Engagement Biomarker, Idea To Endpoint: A Representative Path, Step By Step
The sequence names the intended use first, then sets the tier and qualifies the assay on the platform that fits. Each gate shows the discipline it runs under.
-
1. Context Of Use Named
Proof of target engagement for dose selection is written down, and it sets the tier
-
2. Menu Checked
The 851 item menu searched for the marker and species before any development is bought
-
3. No Kit Reaches It
The analyte sits below kit sensitivity, so a custom MSD assay is built from reagents up
-
4. Qualified To The Tier
Fit-for-purpose qualification, cut points set statistically, in about six to eight weeks
-
5. Samples Flow
Kits out, draws back, batches run as cohorts close, beside the PK from the same accession
-
6. Engagement Answered
Exposure and engagement read together: the dose occupying the target becomes the argument
Why Do Sponsors Choose Our Lab To Set Their Biomarker Validation Tier?
Because the validation-tier call comes before the invoice, so you never pay for rigor the claim does not need.
Get Your Biomarker Strategy Reviewed By PhD Scientists.
Send your plan. We'll flag pitfalls before they cost you.- Biomarker and cytokine assays across MSD, Luminex, ELISA, LC-MS, flow, ELISpot and PCR
- CLIA and CAP for patient-level reporting, GCLP for endpoints, exploratory when honest
- One draw, aliquoted in house, feeding every readout without a second courier or vendor
- About 70% of our work is emerging biotech, so your marker gets senior scientists
Regulated And Inspected By:
Validation Sized To The Claim Your Biomarker Has To Carry
Send the analyte, matrix and decision. A senior scientist checks the menu, names the tier and scopes the path on the platforms linked below.
Related FAQs
What translational directors ask before funding a biomarker, answered.
What does context of use actually change?
Do you already run my analyte?
Which platform will my biomarker run on?
Can the same assay carry from exploratory into the clinic?
How fast can a panel be ready?
Can you run biomarkers for enrollment or stratification?
Multiplex or single analyte?
Explore More Solutions
A biomarker claim usually needs a second, orthogonal readout, and the confirming platform is ours too.
